NCT03689855 Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC Status COMPLETED Phase PHASE2
NCT03650764 Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Status COMPLETED Phase PHASE1/PHASE2
NCT03560973 A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM Status COMPLETED Phase PHASE2
NCT03527108 Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03520946 RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients Status COMPLETED Phase PHASE3
NCT03502746 Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma Status TERMINATED Phase PHASE2
NCT03281369 A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) Status COMPLETED Phase PHASE1/PHASE2
NCT03193918 Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma Status COMPLETED Phase PHASE1
NCT03141034 Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma Status COMPLETED Phase PHASE2
NCT03081143 Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy Status ACTIVE_NOT_RECRUITING Phase PHASE2/PHASE3
NCT03008278 Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery Status COMPLETED Phase PHASE1/PHASE2
NCT02999295 A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT02970539 Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers Status UNKNOWN Phase PHASE1
NCT02934464 Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers Status UNKNOWN Phase PHASE3
NCT02898077 A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Status COMPLETED Phase PHASE3
NCT02831491 A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer Status WITHDRAWN Phase PHASE2
NCT02795858 A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors Status COMPLETED Phase PHASE2
NCT02791334 A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors Status COMPLETED Phase PHASE1
NCT02789345 A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer Status COMPLETED Phase PHASE1
NCT02745769 A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents Status COMPLETED Phase PHASE1